drugset / Trial / NCT00396357

Efficacy/Safety of Vildagliptin and Metformin Combination Therapy in Patients With Type 2 Diabetes Not Well Controlled With Metformin Alone

NCT00396357

Phase 3 Completed 914 enrolled Novartis Pharmaceuticals
RandomizedParallel-groupTriple-blindTreatment

Summary

This study is designed to evaluate the efficacy and safety of vildagliptin in combination with metformin 500 mg bid compared to metformin 1000 mg bid in patients with type 2 diabetes.

Timeline

Start
2006-10
Primary completion
2008-06
Completion

Drugs

EvaluationDrugModalityDoseRoute
Comparator Metformin Small molecule 500 mg
Comparator Metformin Small molecule 1000 mg
Subject Vildagliptin Other / unclassified 100 mg